Evercore ISI Raises Envista (NYSE:NVST) Price Target to $23.00

Envista (NYSE:NVST - Get Free Report) had its price objective increased by research analysts at Evercore ISI from $19.00 to $23.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Evercore ISI's price target points to a potential upside of 12.91% from the stock's previous close.

A number of other research firms have also recently commented on NVST. Bank of America dropped their price objective on Envista from $26.00 to $23.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Morgan Stanley set a $16.00 price objective on Envista in a research report on Tuesday, April 15th. UBS Group dropped their price objective on Envista from $21.00 to $18.00 and set a "neutral" rating for the company in a research report on Monday, May 5th. Baird R W upgraded Envista from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 27th. Finally, Robert W. Baird upgraded Envista from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $21.00 to $23.00 in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $20.23.

Envista Stock Performance

Shares of NYSE NVST traded up $0.22 during mid-day trading on Wednesday, hitting $20.37. 1,738,582 shares of the company were exchanged, compared to its average volume of 2,494,037. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $18.41 and a 200-day simple moving average of $18.48. Envista has a 1-year low of $14.22 and a 1-year high of $23.00. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -3.12, a price-to-earnings-growth ratio of 1.25 and a beta of 1.00.

Envista (NYSE:NVST - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.04. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The company had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. During the same quarter last year, the company earned $0.26 earnings per share. Envista's quarterly revenue was down 1.1% compared to the same quarter last year. On average, sell-side analysts forecast that Envista will post 1 EPS for the current fiscal year.

Institutional Trading of Envista

A number of institutional investors have recently modified their holdings of NVST. Alliancebernstein L.P. lifted its position in Envista by 1,985.1% during the 1st quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company's stock worth $78,547,000 after acquiring an additional 4,332,541 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Envista by 72.6% during the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company's stock valued at $132,223,000 after acquiring an additional 2,882,844 shares in the last quarter. Brickwood Asset Management LLP bought a new position in Envista during the 4th quarter worth $40,037,000. Norges Bank bought a new position in Envista during the 4th quarter worth $38,052,000. Finally, Dimensional Fund Advisors LP grew its stake in Envista by 24.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company's stock worth $144,760,000 after buying an additional 1,625,206 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.